Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers	Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm	Recruiting	Phase 1	2025-10-01		NCT04295863

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
University of Chicago	326

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
SSM Health Cancer Care	Madison	United States	1
University of Chicago Medicine Comprehensive Cancer Center	Chicago	United States	26

Clinical trials